2026 Q1 -tulosraportti
11 päivää sitten
‧46 min
1,55 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 200 | - | - | ||
| 385 | - | - | ||
| 486 | - | - | ||
| 108 | - | - | ||
| 92 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 3 420 | 3 420 | 0 | 3 420 |
| Anonyymi | 442 568 | 442 568 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 3 420 | 3 420 | 0 | 3 420 |
| Anonyymi | 442 568 | 442 568 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 1.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenWhat does GN have to offer after 1-1-27 (as earnings), that no one else has.
·32 min sittenWhy does JPM raise the price target on GN? GN's price target is raised by the American investment bank JPMorgan to 131.80 kr. from 110 kr. This is according to data from Bloomberg News. The recommendation is maintained at "neutral", which the bank has held since spring 2025. When JPMorgan raises the price target on a stock like GN, but at the same time maintains a "neutral" recommendation, it is typically due to a combination of defensive improvements in the company and mathematical adjustments in the analyst's valuation models, rather than a sudden boom in business. Here are the primary reasons why JPMorgan has raised the price target to 131.80 kr.: 1. The large divestment and changed capital structure GN recently completed a historic divestment of its "Hearing" sales division (the hearing aid business). This has had a noticeable effect on the company's balance sheet: Less debt: The money from the divestment comes at a good time and is used to reduce GN's massive debt burden. Lower financial costs: When debt falls, interest expenses also fall. This increases the long-term value of the company per share in analysts' models, which raises the theoretical price target. 2. Share buyback programs After the divestment, GN has announced that they will prioritize share buybacks as a way to distribute capital to investors. When a company buys back its own shares and cancels them, future earnings are spread over fewer shares. This increases earnings per share (EPS), which automatically pulls up a price target. 3. The new savings program Although GN's latest first-quarter report disappointed on revenue and organic growth itself, management reacted quickly by launching a new, comprehensive savings program. The goal is to reduce annual costs by 200 million kr. Banks like JPMorgan include these savings in their estimates for 2026 and 2027. Lower costs mean better profit margins in the long term. Why is the recommendation still only "Neutral"? Although the price target has been raised and indicates a decent potential up to 131.80 kr. compared to the current price (which is fluctuating in the mid-90s), JPMorgan puts on the brakes with a neutral recommendation for two reasons: Weak start to the year: The underlying organic growth in the core business has shown signs of weakness at the start of the year, creating uncertainty as to whether GN can meet its own forecasts. Transition phase: GN is undergoing a major transformation after the divestment. JPMorgan will likely want to see concrete evidence that the savings program is working and that growth is stabilizing before they become real optimists (Buy/Overweight).
·3 t sittenAnyone else besides me biding their time, considering to top up at 90 or below🤔·1 t sittenIt's really not fun 😔 I think everyone has been there. Where you don't cut the loss early enough - because one "hopes" it turns around🤔 And thanks for warning me - because that can turn into bigger losses in my account🤗- ·13.5.should one buy?·13.5.The shorts are buying up in this now. So I dare to as well. Adding here at 94.36
·12.5. · MuokattuYeah!! Officially no longer DK's most shorted stock: ZEALAND PHARMA A/S 10,07 GN STORE NORD A/S 9,99
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
11 päivää sitten
‧46 min
1,55 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenWhat does GN have to offer after 1-1-27 (as earnings), that no one else has.·32 min sittenWhy does JPM raise the price target on GN? GN's price target is raised by the American investment bank JPMorgan to 131.80 kr. from 110 kr. This is according to data from Bloomberg News. The recommendation is maintained at "neutral", which the bank has held since spring 2025. When JPMorgan raises the price target on a stock like GN, but at the same time maintains a "neutral" recommendation, it is typically due to a combination of defensive improvements in the company and mathematical adjustments in the analyst's valuation models, rather than a sudden boom in business. Here are the primary reasons why JPMorgan has raised the price target to 131.80 kr.: 1. The large divestment and changed capital structure GN recently completed a historic divestment of its "Hearing" sales division (the hearing aid business). This has had a noticeable effect on the company's balance sheet: Less debt: The money from the divestment comes at a good time and is used to reduce GN's massive debt burden. Lower financial costs: When debt falls, interest expenses also fall. This increases the long-term value of the company per share in analysts' models, which raises the theoretical price target. 2. Share buyback programs After the divestment, GN has announced that they will prioritize share buybacks as a way to distribute capital to investors. When a company buys back its own shares and cancels them, future earnings are spread over fewer shares. This increases earnings per share (EPS), which automatically pulls up a price target. 3. The new savings program Although GN's latest first-quarter report disappointed on revenue and organic growth itself, management reacted quickly by launching a new, comprehensive savings program. The goal is to reduce annual costs by 200 million kr. Banks like JPMorgan include these savings in their estimates for 2026 and 2027. Lower costs mean better profit margins in the long term. Why is the recommendation still only "Neutral"? Although the price target has been raised and indicates a decent potential up to 131.80 kr. compared to the current price (which is fluctuating in the mid-90s), JPMorgan puts on the brakes with a neutral recommendation for two reasons: Weak start to the year: The underlying organic growth in the core business has shown signs of weakness at the start of the year, creating uncertainty as to whether GN can meet its own forecasts. Transition phase: GN is undergoing a major transformation after the divestment. JPMorgan will likely want to see concrete evidence that the savings program is working and that growth is stabilizing before they become real optimists (Buy/Overweight).
- ·3 t sittenAnyone else besides me biding their time, considering to top up at 90 or below🤔·1 t sittenIt's really not fun 😔 I think everyone has been there. Where you don't cut the loss early enough - because one "hopes" it turns around🤔 And thanks for warning me - because that can turn into bigger losses in my account🤗
- ·13.5.should one buy?·13.5.The shorts are buying up in this now. So I dare to as well. Adding here at 94.36
- ·12.5. · MuokattuYeah!! Officially no longer DK's most shorted stock: ZEALAND PHARMA A/S 10,07 GN STORE NORD A/S 9,99
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 200 | - | - | ||
| 385 | - | - | ||
| 486 | - | - | ||
| 108 | - | - | ||
| 92 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 3 420 | 3 420 | 0 | 3 420 |
| Anonyymi | 442 568 | 442 568 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 3 420 | 3 420 | 0 | 3 420 |
| Anonyymi | 442 568 | 442 568 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 1.5.2025 |
2026 Q1 -tulosraportti
11 päivää sitten
‧46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 5.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 1.5.2025 |
1,55 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenWhat does GN have to offer after 1-1-27 (as earnings), that no one else has.·32 min sittenWhy does JPM raise the price target on GN? GN's price target is raised by the American investment bank JPMorgan to 131.80 kr. from 110 kr. This is according to data from Bloomberg News. The recommendation is maintained at "neutral", which the bank has held since spring 2025. When JPMorgan raises the price target on a stock like GN, but at the same time maintains a "neutral" recommendation, it is typically due to a combination of defensive improvements in the company and mathematical adjustments in the analyst's valuation models, rather than a sudden boom in business. Here are the primary reasons why JPMorgan has raised the price target to 131.80 kr.: 1. The large divestment and changed capital structure GN recently completed a historic divestment of its "Hearing" sales division (the hearing aid business). This has had a noticeable effect on the company's balance sheet: Less debt: The money from the divestment comes at a good time and is used to reduce GN's massive debt burden. Lower financial costs: When debt falls, interest expenses also fall. This increases the long-term value of the company per share in analysts' models, which raises the theoretical price target. 2. Share buyback programs After the divestment, GN has announced that they will prioritize share buybacks as a way to distribute capital to investors. When a company buys back its own shares and cancels them, future earnings are spread over fewer shares. This increases earnings per share (EPS), which automatically pulls up a price target. 3. The new savings program Although GN's latest first-quarter report disappointed on revenue and organic growth itself, management reacted quickly by launching a new, comprehensive savings program. The goal is to reduce annual costs by 200 million kr. Banks like JPMorgan include these savings in their estimates for 2026 and 2027. Lower costs mean better profit margins in the long term. Why is the recommendation still only "Neutral"? Although the price target has been raised and indicates a decent potential up to 131.80 kr. compared to the current price (which is fluctuating in the mid-90s), JPMorgan puts on the brakes with a neutral recommendation for two reasons: Weak start to the year: The underlying organic growth in the core business has shown signs of weakness at the start of the year, creating uncertainty as to whether GN can meet its own forecasts. Transition phase: GN is undergoing a major transformation after the divestment. JPMorgan will likely want to see concrete evidence that the savings program is working and that growth is stabilizing before they become real optimists (Buy/Overweight).
- ·3 t sittenAnyone else besides me biding their time, considering to top up at 90 or below🤔·1 t sittenIt's really not fun 😔 I think everyone has been there. Where you don't cut the loss early enough - because one "hopes" it turns around🤔 And thanks for warning me - because that can turn into bigger losses in my account🤗
- ·13.5.should one buy?·13.5.The shorts are buying up in this now. So I dare to as well. Adding here at 94.36
- ·12.5. · MuokattuYeah!! Officially no longer DK's most shorted stock: ZEALAND PHARMA A/S 10,07 GN STORE NORD A/S 9,99
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 200 | - | - | ||
| 385 | - | - | ||
| 486 | - | - | ||
| 108 | - | - | ||
| 92 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 3 420 | 3 420 | 0 | 3 420 |
| Anonyymi | 442 568 | 442 568 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 3 420 | 3 420 | 0 | 3 420 |
| Anonyymi | 442 568 | 442 568 | 0 | 0 |